Timothy J Miles
Overview
Explore the profile of Timothy J Miles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
422
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fernow J, Olliver M, Couet W, Lagrange S, Lamers M, Olesen O, et al.
Nat Rev Drug Discov
. 2024 Sep;
24(1):1-2.
PMID: 39313598
No abstract available.
2.
Thomas M, McGonagle K, Rowland P, Robinson D, Dodd P, Camino-Diaz I, et al.
J Med Chem
. 2023 Jul;
66(15):10413-10431.
PMID: 37506194
There is an urgent need for new treatments for Chagas disease, a parasitic infection which mostly impacts South and Central America. We previously reported on the discovery of GSK3494245/DDD01305143, a...
3.
Wyllie S, Thomas M, Patterson S, Crouch S, De Rycker M, Lowe R, et al.
Nature
. 2023 Jul;
619(7970):E48.
PMID: 37402863
No abstract available.
4.
Thomas M, Brand S, De Rycker M, Zuccotto F, Lukac I, Dodd P, et al.
J Med Chem
. 2021 Apr;
64(9):5905-5930.
PMID: 33904304
There is an urgent need for new treatments for visceral leishmaniasis (VL), a parasitic infection which impacts heavily large areas of East Africa, Asia, and South America. We previously reported...
5.
Thomas M, De Rycker M, Ajakane M, Crouch S, Campbell L, Daugan A, et al.
RSC Med Chem
. 2021 Jan;
11(10):1168-1177.
PMID: 33479621
Visceral leishmaniasis (VL) affects millions of people across the world, largely in developing nations. It is fatal if left untreated and the current treatments are inadequate. As such, there is...
6.
Thomas M, De Rycker M, Wall R, Spinks D, Epemolu O, Manthri S, et al.
J Med Chem
. 2020 Jul;
63(17):9523-9539.
PMID: 32663005
Visceral leishmaniasis (VL) is a parasitic infection that results in approximately 26 000-65 000 deaths annually. The available treatments are hampered by issues such as toxicity, variable efficacy, and unsuitable...
7.
Wall R, Carvalho S, Milne R, Bueren-Calabuig J, Moniz S, Cantizani-Perez J, et al.
ACS Infect Dis
. 2020 Jan;
6(3):515-528.
PMID: 31967783
Available treatments for Chagas' disease and visceral leishmaniasis are inadequate, and there is a pressing need for new therapeutics. Drug discovery efforts for both diseases principally rely upon phenotypic screening....
8.
De Rycker M, Horn D, Aldridge B, Amewu R, Barry 3rd C, Buckner F, et al.
ACS Infect Dis
. 2019 Dec;
6(1):3-13.
PMID: 31808676
In May 2019, the Wellcome Centre for Anti-Infectives Research (CAIR) at the University of Dundee, UK, held an international conference with the aim of discussing some key questions around discovering...
9.
Velasco R, Guerrero C, Fra G, Moure A, Miguel-Siles J, Quesada-Campos M, et al.
Tetrahedron Lett
. 2019 May;
60(18):1243-1247.
PMID: 31057189
During the course of a research program aimed at identifying novel antileishmanial compounds, a multi-gram synthesis of -(-4-((4-methoxy-3-(()-3-methylmorpholino)-1-pyrazolo[3,4-]pyrimidin-6-yl)amino)cyclohexyl)-2-methylpropane-1-sulfonamide (( )) was required. This letter describes optimisation of the reaction conditions...
10.
Wyllie S, Brand S, Thomas M, De Rycker M, Chung C, Pena I, et al.
Proc Natl Acad Sci U S A
. 2019 Apr;
116(19):9318-9323.
PMID: 30962368
Visceral leishmaniasis (VL), caused by the protozoan parasites and , is one of the major parasitic diseases worldwide. There is an urgent need for new drugs to treat VL, because...